0
USD
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Research Report 2020
Published Date: March 2020
|
Report Code: QYRE-Auto-24S1834
Home | Category |Health |Pharmacy |Drugs & Medications
Global Irritable Bowel Syndrome with Diarrhea IBS D Drugs Market Research Report 2020

Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Research Report 2020

Code: QYRE-Auto-24S1834
Report
March 2020
93 Pages
QYResearch
Region: Global, China, North America, Europe, France, Germany, Italy,
Description
Table of Content
Tables & Figures
The global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market is valued at US$ xx million in 2020 is expected to reach US$ xx million by the end of 2026, growing at a CAGR of xx% during 2021-2026.
This report focuses on Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan etc.
Market Segment Analysis
The research report includes specific segments by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type, the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market is segmented into
    Preface
    Eluxadoline
    Alosetron
    Rifaximin
    Loperamide
    Diphenoxylate + Atropine
    Dicyclomine and Hyoscyamine
Segment by Application
    Hospitals
    Clinics
    Others
 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market: Regional Analysis
The Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market is analysed and market size information is provided by regions (countries). The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type and by Application segment in terms of sales and revenue for the period 2015-2026.
The key regions covered in the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market report are:
North America
    U.S.
    Canada
Europe
    Germany
    France
    U.K.
    Italy
    Russia
Asia-Pacific
    China
    Japan
    South Korea
    India
    Australia
    Taiwan
    Indonesia
    Thailand
    Malaysia
    Philippines
    Vietnam
Latin America
    Mexico
    Brazil
    Argentina
Middle East & Africa
    Turkey
    Saudi Arabia
    U.A.E
Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market: Competitive Analysis
This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2015 to 2019.
The major players in global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market include:
    Astellas Pharmaceuticals
    Actavis
    Pfizer
    GlaxoSmithKline
    Salix Pharmaceuticals Ltd
    AstraZenenca
Table of Contents
1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Overview
1.1 Product Overview and Scope of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
1.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Type
1.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate Comparison by Type (2021-2026)
1.2.2 Preface
1.2.3 Eluxadoline
1.2.4 Alosetron
1.2.5 Rifaximin
1.2.6 Loperamide
1.2.7 Diphenoxylate + Atropine
1.2.8 Dicyclomine and Hyoscyamine
1.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Application
1.3.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Comparison by Application: 2020 VS 2026
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Estimates and Forecasts
1.4.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue 2015-2026
1.4.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales 2015-2026
1.4.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Region: 2020 Versus 2026
2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Competition by Manufacturers
2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Manufacturers (2015-2020)
2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Manufacturers (2015-2020)
2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Price by Manufacturers (2015-2020)
2.4 Manufacturers Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Sites, Area Served, Product Type
2.5 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Competitive Situation and Trends
2.5.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Concentration Rate
2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue
2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
2.7 Primary Interviews with Key Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Players (Opinion Leaders)
3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Retrospective Market Scenario by Region
3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3.3 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Country
3.3.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country
3.3.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Country
3.4.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country
3.4.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Region
3.5.1 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region
3.5.2 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Country
3.6.1 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country
3.6.2 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country
3.6.3 Mexico
3.6.3 Brazil
3.6.3 Argentina
3.7 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Country
3.7.1 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country
3.7.2 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Historic Market Analysis by Type
4.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2015-2020)
4.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Type (2015-2020)
4.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price Market Share by Type (2015-2020)
4.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Historic Market Analysis by Application
5.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Application (2015-2020)
5.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Application (2015-2020)
5.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Application (2015-2020)
6 Company Profiles and Key Figures in Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business
6.1 Astellas Pharmaceuticals
6.1.1 Corporation Information
6.1.2 Astellas Pharmaceuticals Description, Business Overview and Total Revenue
6.1.3 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2015-2020)
6.1.4 Astellas Pharmaceuticals Products Offered
6.1.5 Astellas Pharmaceuticals Recent Development
6.2 Actavis
6.2.1 Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Sites and Area Served
6.2.2 Actavis Description, Business Overview and Total Revenue
6.2.3 Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2015-2020)
6.2.4 Actavis Products Offered
6.2.5 Actavis Recent Development
6.3 Pfizer
6.3.1 Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Sites and Area Served
6.3.2 Pfizer Description, Business Overview and Total Revenue
6.3.3 Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2015-2020)
6.3.4 Pfizer Products Offered
6.3.5 Pfizer Recent Development
6.4 GlaxoSmithKline
6.4.1 GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Sites and Area Served
6.4.2 GlaxoSmithKline Description, Business Overview and Total Revenue
6.4.3 GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2015-2020)
6.4.4 GlaxoSmithKline Products Offered
6.4.5 GlaxoSmithKline Recent Development
6.5 Salix Pharmaceuticals Ltd
6.5.1 Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Sites and Area Served
6.5.2 Salix Pharmaceuticals Ltd Description, Business Overview and Total Revenue
6.5.3 Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2015-2020)
6.5.4 Salix Pharmaceuticals Ltd Products Offered
6.5.5 Salix Pharmaceuticals Ltd Recent Development
6.6 AstraZenenca
6.6.1 AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Sites and Area Served
6.6.2 AstraZenenca Description, Business Overview and Total Revenue
6.6.3 AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2015-2020)
6.6.4 AstraZenenca Products Offered
6.6.5 AstraZenenca Recent Development
7 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Cost Analysis
7.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Raw Materials Price Trend
7.1.3 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
7.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Distributors List
8.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Customers
9 Market Dynamics
9.1 Market Trends
9.2 Opportunities and Drivers
9.3 Challenges
9.4 Porter's Five Forces Analysis
10 Global Market Forecast
10.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Type (2021-2026)
10.1.2 Global Forecasted Revenue of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Type (2021-2026)
10.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Application (2021-2026)
10.2.2 Global Forecasted Revenue of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Application (2021-2026)
10.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Region (2021-2026)
10.3.2 Global Forecasted Revenue of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Region (2021-2026)
10.4 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Estimates and Projections (2021-2026)
10.5 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Estimates and Projections (2021-2026)
10.6 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Estimates and Projections (2021-2026)
10.7 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Estimates and Projections (2021-2026)
10.8 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Estimates and Projections (2021-2026)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
    Table 1. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT) Growth Rate Comparison by Type (2015-2026)
    Table 2. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT) Comparison by Application: 2020 VS 2026
    Table 3. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Type (K MT) (US$ Million) (2020 VS 2026)
    Table 4. Global Key Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturers Covered in This Study
    Table 5. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT) by Manufacturers (2015-2020)
    Table 6. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Manufacturers (2015-2020)
    Table 7. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Million USD) by Manufacturers (2015-2020)
    Table 8. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Manufacturers (2015-2020)
    Table 9. Global Market Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Price (USD/MT) of Key Manufacturers (2015-2020)
    Table 10. Manufacturers Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Sites and Area Served
    Table 11. Manufacturers Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Types
    Table 12. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 13. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs as of 2019)
    Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 15. Main Points Interviewed from Key Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Players
    Table 16. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT) by Region (2015-2020)
    Table 17. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region (2015-2020)
    Table 18. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Million US$) by Region (2015-2020)
    Table 19. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region (2015-2020)
    Table 20. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2015-2020) (K MT)
    Table 21. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2015-2020)
    Table 22. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2015-2020) (US$ Million)
    Table 23. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2015-2020)
    Table 24. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2015-2020) (K MT)
    Table 25. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2015-2020)
    Table 26. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2015-2020) (US$ Million)
    Table 27. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2015-2020)
    Table 28. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2015-2020) (K MT)
    Table 29. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region (2015-2020)
    Table 30. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2015-2020) (US$ Million)
    Table 31. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region (2015-2020)
    Table 32. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2015-2020) (K MT)
    Table 33. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2015-2020)
    Table 34. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2015-2020) (US$ Million)
    Table 35. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2015-2020)
    Table 36. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2015-2020) (K MT)
    Table 37. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2015-2020)
    Table 38. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2015-2020) (US$ Million)
    Table 39. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2015-2020)
    Table 40. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT) by Type (2015-2020)
    Table 41. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Type (2015-2020)
    Table 42. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Million US$) by Type (2015-2020)
    Table 43. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Type (2015-2020)
    Table 44. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/MT) by Type (2015-2020)
    Table 45. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT) by Application (2015-2020)
    Table 46. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Application (2015-2020)
    Table 47. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate by Application (2015-2020)
    Table 48. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Corporation Information
    Table 49. Astellas Pharmaceuticals Description and Business Overview
    Table 50. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020)
    Table 51. Astellas Pharmaceuticals Main Product
    Table 52. Astellas Pharmaceuticals Recent Development
    Table 53. Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Corporation Information
    Table 54. Actavis Corporation Information
    Table 55. Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020)
    Table 56. Actavis Main Product
    Table 57. Actavis Recent Development
    Table 58. Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Corporation Information
    Table 59. Pfizer Corporation Information
    Table 60. Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020)
    Table 61. Pfizer Main Product
    Table 62. Pfizer Recent Development
    Table 63. GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Corporation Information
    Table 64. GlaxoSmithKline Corporation Information
    Table 65. GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020)
    Table 66. GlaxoSmithKline Main Product
    Table 67. GlaxoSmithKline Recent Development
    Table 68. Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Corporation Information
    Table 69. Salix Pharmaceuticals Ltd Corporation Information
    Table 70. Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020)
    Table 71. Salix Pharmaceuticals Ltd Main Product
    Table 72. Salix Pharmaceuticals Ltd Recent Development
    Table 73. AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Corporation Information
    Table 74. AstraZenenca Corporation Information
    Table 75. AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020)
    Table 76. AstraZenenca Main Product
    Table 77. AstraZenenca Recent Development
    Table 78. Sales Base and Market Concentration Rate of Raw Material
    Table 79. Key Suppliers of Raw Materials
    Table 80. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Distributors List
    Table 81. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Customers List
    Table 82. Market Key Trends
    Table 83. Key Opportunities and Drivers: Impact Analysis (2021-2026)
    Table 84. Key Challenges
    Table 85. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT) Forecast by Type (2021-2026)
    Table 86. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share Forecast by Type (2021-2026)
    Table 87. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Million US$) Forecast by Type (2021-2026)
    Table 88. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Million US$) Market Share Forecast by Type (2021-2026)
    Table 89. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT) Forecast by Application (2021-2026)
    Table 90. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Million US$) Forecast by Application (2021-2026)
    Table 91. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT) Forecast by Region (2021-2026)
    Table 92. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share Forecast by Region (2021-2026)
    Table 93. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Region (2021-2026) (US$ Million)
    Table 94. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share Forecast by Region (2021-2026)
    Table 95. Research Programs/Design for This Report
    Table 96. Key Data Information from Secondary Sources
    Table 97. Key Data Information from Primary Sources
List of Figures
    Figure 1. Picture of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
    Figure 2. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type: 2020 VS 2026
    Figure 3. Preface Product Picture
    Figure 4. Eluxadoline Product Picture
    Figure 5. Alosetron Product Picture
    Figure 6. Rifaximin Product Picture
    Figure 7. Loperamide Product Picture
    Figure 8. Diphenoxylate + Atropine Product Picture
    Figure 9. Dicyclomine and Hyoscyamine Product Picture
    Figure 10. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Application: 2020 VS 2026
    Figure 11. Hospitals
    Figure 12. Clinics
    Figure 13. Others
    Figure 14. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size 2015-2026 (US$ Million)
    Figure 15. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Capacity (K MT) (2015-2026)
    Figure 16. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Market Share by Region: 2020 Versus 2026
    Figure 17. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Manufacturers in 2020
    Figure 18. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Manufacturers in 2019
    Figure 19. The Global 5 and 10 Largest Players: Market Share by Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue in 2019
    Figure 20. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
    Figure 21. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region (2015-2020)
    Figure 22. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region in 2019
    Figure 23. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region (2015-2020)
    Figure 24. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region in 2019
    Figure 25. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country in 2019
    Figure 26. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country in 2019
    Figure 27. U.S. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 28. U.S. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 29. Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 30. Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 31. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country in 2019
    Figure 32. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country in 2019
    Figure 33. Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 34. Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 35. France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 36. France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 37. U.K. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 38. U.K. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 39. Italy Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 40. Italy Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 41. Russia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 42. Russia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 43. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region in 2019
    Figure 44. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region in 2019
    Figure 45. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 46. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 47. Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 48. Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 49. South Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 50. South Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 51. India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 52. India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 53. Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 54. Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 55. Taiwan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 56. Taiwan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 57. Indonesia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 58. Indonesia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 59. Thailand Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 60. Thailand Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 61. Malaysia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 62. Malaysia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 63. Philippines Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 64. Philippines Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 65. Vietnam Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 66. Vietnam Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 67. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country in 2019
    Figure 68. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country in 2019
    Figure 69. Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 70. Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 71. Brazil Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 72. Brazil Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 73. Argentina Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 74. Argentina Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 75. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country in 2019
    Figure 76. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country in 2019
    Figure 77. Turkey Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 78. Turkey Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 79. Saudi Arabia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 80. Saudi Arabia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 81. U.A.E Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 82. U.A.E Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 83. Sales Market Share of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Type (2015-2020)
    Figure 84. Sales Market Share of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Type in 2019
    Figure 85. Revenue Share of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Type (2015-2020)
    Figure 86. Revenue Market Share of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Type in 2019
    Figure 87. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth by Type (2015-2020) (K MT)
    Figure 88. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Application (2015-2020)
    Figure 89. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Application in 2019
    Figure 90. Global Revenue Share of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Application (2015-2020)
    Figure 91. Global Revenue Share of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Application in 2020
    Figure 92. Astellas Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
    Figure 93. Actavis Total Revenue (US$ Million): 2019 Compared with 2018
    Figure 94. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
    Figure 95. GlaxoSmithKline Total Revenue (US$ Million): 2019 Compared with 2018
    Figure 96. Salix Pharmaceuticals Ltd Total Revenue (US$ Million): 2019 Compared with 2018
    Figure 97. AstraZenenca Total Revenue (US$ Million): 2019 Compared with 2018
    Figure 98. Price Trend of Key Raw Materials
    Figure 99. Manufacturing Cost Structure of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
    Figure 100. Manufacturing Process Analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
    Figure 101. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industrial Chain Analysis
    Figure 102. Channels of Distribution
    Figure 103. Distributors Profiles
    Figure 104. Porter's Five Forces Analysis
    Figure 105. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT) and Growth Rate Forecast (2021-2026)
    Figure 106. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Million US$) and Growth Rate Forecast (2021-2026)
    Figure 107. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT) and Growth Rate Forecast (2021-2026)
    Figure 108. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Million US$) and Growth Rate Forecast (2021-2026)
    Figure 109. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT) and Growth Rate Forecast (2021-2026)
    Figure 110. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Million US$) and Growth Rate Forecast (2021-2026)
    Figure 111. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT) and Growth Rate Forecast (2021-2026)
    Figure 112. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Million US$) and Growth Rate Forecast (2021-2026)
    Figure 113. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT) and Growth Rate Forecast (2021-2026)
    Figure 114. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Million US$) and Growth Rate Forecast (2021-2026)
    Figure 115. Bottom-up and Top-down Approaches for This Report
    Figure 116. Data Triangulation
    Figure 117. Key Executives Interviewed
The global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market is valued at US$ xx million in 2020 is expected to reach US$ xx million by the end of 2026, growing at a CAGR of xx% during 2021-2026.
This report focuses on Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan etc.
Market Segment Analysis
The research report includes specific segments by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type, the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market is segmented into
    Preface
    Eluxadoline
    Alosetron
    Rifaximin
    Loperamide
    Diphenoxylate + Atropine
    Dicyclomine and Hyoscyamine
Segment by Application
    Hospitals
    Clinics
    Others
 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market: Regional Analysis
The Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market is analysed and market size information is provided by regions (countries). The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type and by Application segment in terms of sales and revenue for the period 2015-2026.
The key regions covered in the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market report are:
North America
    U.S.
    Canada
Europe
    Germany
    France
    U.K.
    Italy
    Russia
Asia-Pacific
    China
    Japan
    South Korea
    India
    Australia
    Taiwan
    Indonesia
    Thailand
    Malaysia
    Philippines
    Vietnam
Latin America
    Mexico
    Brazil
    Argentina
Middle East & Africa
    Turkey
    Saudi Arabia
    U.A.E
Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market: Competitive Analysis
This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2015 to 2019.
The major players in global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market include:
    Astellas Pharmaceuticals
    Actavis
    Pfizer
    GlaxoSmithKline
    Salix Pharmaceuticals Ltd
    AstraZenenca
Read More
Table of Contents
1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Overview
1.1 Product Overview and Scope of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
1.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Type
1.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate Comparison by Type (2021-2026)
1.2.2 Preface
1.2.3 Eluxadoline
1.2.4 Alosetron
1.2.5 Rifaximin
1.2.6 Loperamide
1.2.7 Diphenoxylate + Atropine
1.2.8 Dicyclomine and Hyoscyamine
1.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Application
1.3.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Comparison by Application: 2020 VS 2026
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Estimates and Forecasts
1.4.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue 2015-2026
1.4.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales 2015-2026
1.4.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Region: 2020 Versus 2026
2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Competition by Manufacturers
2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Manufacturers (2015-2020)
2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Manufacturers (2015-2020)
2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Price by Manufacturers (2015-2020)
2.4 Manufacturers Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Sites, Area Served, Product Type
2.5 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Competitive Situation and Trends
2.5.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Concentration Rate
2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue
2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
2.7 Primary Interviews with Key Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Players (Opinion Leaders)
3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Retrospective Market Scenario by Region
3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3.3 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Country
3.3.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country
3.3.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Country
3.4.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country
3.4.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Region
3.5.1 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region
3.5.2 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Country
3.6.1 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country
3.6.2 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country
3.6.3 Mexico
3.6.3 Brazil
3.6.3 Argentina
3.7 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Country
3.7.1 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country
3.7.2 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Historic Market Analysis by Type
4.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2015-2020)
4.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Type (2015-2020)
4.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price Market Share by Type (2015-2020)
4.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Historic Market Analysis by Application
5.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Application (2015-2020)
5.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Application (2015-2020)
5.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Application (2015-2020)
6 Company Profiles and Key Figures in Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business
6.1 Astellas Pharmaceuticals
6.1.1 Corporation Information
6.1.2 Astellas Pharmaceuticals Description, Business Overview and Total Revenue
6.1.3 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2015-2020)
6.1.4 Astellas Pharmaceuticals Products Offered
6.1.5 Astellas Pharmaceuticals Recent Development
6.2 Actavis
6.2.1 Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Sites and Area Served
6.2.2 Actavis Description, Business Overview and Total Revenue
6.2.3 Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2015-2020)
6.2.4 Actavis Products Offered
6.2.5 Actavis Recent Development
6.3 Pfizer
6.3.1 Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Sites and Area Served
6.3.2 Pfizer Description, Business Overview and Total Revenue
6.3.3 Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2015-2020)
6.3.4 Pfizer Products Offered
6.3.5 Pfizer Recent Development
6.4 GlaxoSmithKline
6.4.1 GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Sites and Area Served
6.4.2 GlaxoSmithKline Description, Business Overview and Total Revenue
6.4.3 GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2015-2020)
6.4.4 GlaxoSmithKline Products Offered
6.4.5 GlaxoSmithKline Recent Development
6.5 Salix Pharmaceuticals Ltd
6.5.1 Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Sites and Area Served
6.5.2 Salix Pharmaceuticals Ltd Description, Business Overview and Total Revenue
6.5.3 Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2015-2020)
6.5.4 Salix Pharmaceuticals Ltd Products Offered
6.5.5 Salix Pharmaceuticals Ltd Recent Development
6.6 AstraZenenca
6.6.1 AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Sites and Area Served
6.6.2 AstraZenenca Description, Business Overview and Total Revenue
6.6.3 AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2015-2020)
6.6.4 AstraZenenca Products Offered
6.6.5 AstraZenenca Recent Development
7 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Cost Analysis
7.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Raw Materials Price Trend
7.1.3 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
7.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Distributors List
8.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Customers
9 Market Dynamics
9.1 Market Trends
9.2 Opportunities and Drivers
9.3 Challenges
9.4 Porter's Five Forces Analysis
10 Global Market Forecast
10.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Type (2021-2026)
10.1.2 Global Forecasted Revenue of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Type (2021-2026)
10.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Application (2021-2026)
10.2.2 Global Forecasted Revenue of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Application (2021-2026)
10.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Region (2021-2026)
10.3.2 Global Forecasted Revenue of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Region (2021-2026)
10.4 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Estimates and Projections (2021-2026)
10.5 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Estimates and Projections (2021-2026)
10.6 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Estimates and Projections (2021-2026)
10.7 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Estimates and Projections (2021-2026)
10.8 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Estimates and Projections (2021-2026)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
Read More
List of Tables
    Table 1. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT) Growth Rate Comparison by Type (2015-2026)
    Table 2. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT) Comparison by Application: 2020 VS 2026
    Table 3. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Type (K MT) (US$ Million) (2020 VS 2026)
    Table 4. Global Key Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturers Covered in This Study
    Table 5. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT) by Manufacturers (2015-2020)
    Table 6. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Manufacturers (2015-2020)
    Table 7. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Million USD) by Manufacturers (2015-2020)
    Table 8. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Manufacturers (2015-2020)
    Table 9. Global Market Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Price (USD/MT) of Key Manufacturers (2015-2020)
    Table 10. Manufacturers Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Sites and Area Served
    Table 11. Manufacturers Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Types
    Table 12. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 13. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs as of 2019)
    Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 15. Main Points Interviewed from Key Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Players
    Table 16. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT) by Region (2015-2020)
    Table 17. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region (2015-2020)
    Table 18. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Million US$) by Region (2015-2020)
    Table 19. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region (2015-2020)
    Table 20. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2015-2020) (K MT)
    Table 21. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2015-2020)
    Table 22. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2015-2020) (US$ Million)
    Table 23. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2015-2020)
    Table 24. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2015-2020) (K MT)
    Table 25. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2015-2020)
    Table 26. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2015-2020) (US$ Million)
    Table 27. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2015-2020)
    Table 28. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2015-2020) (K MT)
    Table 29. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region (2015-2020)
    Table 30. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2015-2020) (US$ Million)
    Table 31. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region (2015-2020)
    Table 32. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2015-2020) (K MT)
    Table 33. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2015-2020)
    Table 34. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2015-2020) (US$ Million)
    Table 35. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2015-2020)
    Table 36. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2015-2020) (K MT)
    Table 37. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2015-2020)
    Table 38. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2015-2020) (US$ Million)
    Table 39. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2015-2020)
    Table 40. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT) by Type (2015-2020)
    Table 41. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Type (2015-2020)
    Table 42. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Million US$) by Type (2015-2020)
    Table 43. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Type (2015-2020)
    Table 44. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/MT) by Type (2015-2020)
    Table 45. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT) by Application (2015-2020)
    Table 46. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Application (2015-2020)
    Table 47. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate by Application (2015-2020)
    Table 48. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Corporation Information
    Table 49. Astellas Pharmaceuticals Description and Business Overview
    Table 50. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020)
    Table 51. Astellas Pharmaceuticals Main Product
    Table 52. Astellas Pharmaceuticals Recent Development
    Table 53. Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Corporation Information
    Table 54. Actavis Corporation Information
    Table 55. Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020)
    Table 56. Actavis Main Product
    Table 57. Actavis Recent Development
    Table 58. Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Corporation Information
    Table 59. Pfizer Corporation Information
    Table 60. Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020)
    Table 61. Pfizer Main Product
    Table 62. Pfizer Recent Development
    Table 63. GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Corporation Information
    Table 64. GlaxoSmithKline Corporation Information
    Table 65. GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020)
    Table 66. GlaxoSmithKline Main Product
    Table 67. GlaxoSmithKline Recent Development
    Table 68. Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Corporation Information
    Table 69. Salix Pharmaceuticals Ltd Corporation Information
    Table 70. Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020)
    Table 71. Salix Pharmaceuticals Ltd Main Product
    Table 72. Salix Pharmaceuticals Ltd Recent Development
    Table 73. AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Corporation Information
    Table 74. AstraZenenca Corporation Information
    Table 75. AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020)
    Table 76. AstraZenenca Main Product
    Table 77. AstraZenenca Recent Development
    Table 78. Sales Base and Market Concentration Rate of Raw Material
    Table 79. Key Suppliers of Raw Materials
    Table 80. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Distributors List
    Table 81. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Customers List
    Table 82. Market Key Trends
    Table 83. Key Opportunities and Drivers: Impact Analysis (2021-2026)
    Table 84. Key Challenges
    Table 85. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT) Forecast by Type (2021-2026)
    Table 86. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share Forecast by Type (2021-2026)
    Table 87. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Million US$) Forecast by Type (2021-2026)
    Table 88. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Million US$) Market Share Forecast by Type (2021-2026)
    Table 89. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT) Forecast by Application (2021-2026)
    Table 90. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Million US$) Forecast by Application (2021-2026)
    Table 91. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT) Forecast by Region (2021-2026)
    Table 92. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share Forecast by Region (2021-2026)
    Table 93. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Region (2021-2026) (US$ Million)
    Table 94. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share Forecast by Region (2021-2026)
    Table 95. Research Programs/Design for This Report
    Table 96. Key Data Information from Secondary Sources
    Table 97. Key Data Information from Primary Sources
List of Figures
    Figure 1. Picture of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
    Figure 2. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type: 2020 VS 2026
    Figure 3. Preface Product Picture
    Figure 4. Eluxadoline Product Picture
    Figure 5. Alosetron Product Picture
    Figure 6. Rifaximin Product Picture
    Figure 7. Loperamide Product Picture
    Figure 8. Diphenoxylate + Atropine Product Picture
    Figure 9. Dicyclomine and Hyoscyamine Product Picture
    Figure 10. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Application: 2020 VS 2026
    Figure 11. Hospitals
    Figure 12. Clinics
    Figure 13. Others
    Figure 14. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size 2015-2026 (US$ Million)
    Figure 15. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Capacity (K MT) (2015-2026)
    Figure 16. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Market Share by Region: 2020 Versus 2026
    Figure 17. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Manufacturers in 2020
    Figure 18. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Manufacturers in 2019
    Figure 19. The Global 5 and 10 Largest Players: Market Share by Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue in 2019
    Figure 20. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
    Figure 21. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region (2015-2020)
    Figure 22. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region in 2019
    Figure 23. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region (2015-2020)
    Figure 24. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region in 2019
    Figure 25. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country in 2019
    Figure 26. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country in 2019
    Figure 27. U.S. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 28. U.S. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 29. Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 30. Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 31. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country in 2019
    Figure 32. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country in 2019
    Figure 33. Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 34. Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 35. France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 36. France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 37. U.K. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 38. U.K. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 39. Italy Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 40. Italy Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 41. Russia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 42. Russia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 43. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region in 2019
    Figure 44. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region in 2019
    Figure 45. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 46. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 47. Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 48. Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 49. South Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 50. South Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 51. India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 52. India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 53. Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 54. Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 55. Taiwan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 56. Taiwan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 57. Indonesia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 58. Indonesia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 59. Thailand Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 60. Thailand Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 61. Malaysia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 62. Malaysia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 63. Philippines Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 64. Philippines Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 65. Vietnam Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 66. Vietnam Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 67. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country in 2019
    Figure 68. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country in 2019
    Figure 69. Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 70. Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 71. Brazil Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 72. Brazil Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 73. Argentina Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 74. Argentina Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 75. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country in 2019
    Figure 76. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country in 2019
    Figure 77. Turkey Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 78. Turkey Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 79. Saudi Arabia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 80. Saudi Arabia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 81. U.A.E Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2015-2020) (K MT)
    Figure 82. U.A.E Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
    Figure 83. Sales Market Share of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Type (2015-2020)
    Figure 84. Sales Market Share of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Type in 2019
    Figure 85. Revenue Share of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Type (2015-2020)
    Figure 86. Revenue Market Share of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Type in 2019
    Figure 87. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth by Type (2015-2020) (K MT)
    Figure 88. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Application (2015-2020)
    Figure 89. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Application in 2019
    Figure 90. Global Revenue Share of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Application (2015-2020)
    Figure 91. Global Revenue Share of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Application in 2020
    Figure 92. Astellas Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
    Figure 93. Actavis Total Revenue (US$ Million): 2019 Compared with 2018
    Figure 94. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
    Figure 95. GlaxoSmithKline Total Revenue (US$ Million): 2019 Compared with 2018
    Figure 96. Salix Pharmaceuticals Ltd Total Revenue (US$ Million): 2019 Compared with 2018
    Figure 97. AstraZenenca Total Revenue (US$ Million): 2019 Compared with 2018
    Figure 98. Price Trend of Key Raw Materials
    Figure 99. Manufacturing Cost Structure of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
    Figure 100. Manufacturing Process Analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
    Figure 101. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industrial Chain Analysis
    Figure 102. Channels of Distribution
    Figure 103. Distributors Profiles
    Figure 104. Porter's Five Forces Analysis
    Figure 105. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT) and Growth Rate Forecast (2021-2026)
    Figure 106. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Million US$) and Growth Rate Forecast (2021-2026)
    Figure 107. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT) and Growth Rate Forecast (2021-2026)
    Figure 108. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Million US$) and Growth Rate Forecast (2021-2026)
    Figure 109. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT) and Growth Rate Forecast (2021-2026)
    Figure 110. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Million US$) and Growth Rate Forecast (2021-2026)
    Figure 111. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT) and Growth Rate Forecast (2021-2026)
    Figure 112. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Million US$) and Growth Rate Forecast (2021-2026)
    Figure 113. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT) and Growth Rate Forecast (2021-2026)
    Figure 114. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Million US$) and Growth Rate Forecast (2021-2026)
    Figure 115. Bottom-up and Top-down Approaches for This Report
    Figure 116. Data Triangulation
    Figure 117. Key Executives Interviewed
Read More
SELECT A FORMAT
Added to Cart

Single User

Electronic (PDF)
$2900
This license allows only one user(purchaser of the report) to access the PDF.

Multi User

Electronic (PDF)
$4350
This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)
$5800
This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Leap India

RELATED REPORTS

Global Paclitaxel Injection Market Research Report 2021
Global Paclitaxel Injection Market Research Report 2021

120 Pages
Type: Report
Code: QYRE-Auto-5J4435
Thu Feb 04 00:00:00 UTC 2021

Add to Cart

Global Myotonic Dystrophy Medication Market Size Status and Forecast 2021 2027
Global Myotonic Dystrophy Medication Market Size, Status and Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-10R4400
Thu Feb 04 00:00:00 UTC 2021

Add to Cart

Global Acne Treatment Drug Market Size Status and Forecast 2021 2027
Global Acne Treatment Drug Market Size, Status and Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-10B4399
Thu Feb 04 00:00:00 UTC 2021

Add to Cart

Global Coronavirus Treatment Drugs Market Size Status and Forecast 2021 2027
Global Coronavirus Treatment Drugs Market Size, Status and Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-37M4166
Thu Feb 04 00:00:00 UTC 2021

Add to Cart

0 Items
X
No items in the cart.
$0.0